News

FDA cell and gene therapy director exit increases ‘volatility’ for sector
Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...
BioPharma Dive2h
Gene therapy faces fresh uncertainty as two more top FDA officials depart
The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...
Investor's Business Daily on MSN2h
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.
Gene editors steady despite latest leadership shake-up at FDA
Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...
Medical Marketing & Media5h
Rx Rundown: Sanofi, Processa Pharmaceuticals, Eli Lilly and more
AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.